{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:41:33Z","timestamp":1789062093724,"version":"build-2803163510"},"reference-count":23,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Major Specific Project of Sichuan Province of China","award":["2020YFS0034"],"award-info":[{"award-number":["2020YFS0034"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903722"],"award-info":[{"award-number":["81903722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Uricosuric agents are the typical approach to the control of hyperuricemia; however, their use has been eclipsed by adverse reactions, and a safer uricosuric drug is badly needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>HP501 is a novel renal urate transporter 1 inhibitor for the treatment of hyperuricemia. In this first-in-human study, we investigated the safety, efficacy, and pharmacokinetics of HP501 in healthy volunteers and hyperuricemic patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The placebo-controlled, double-blind, randomized, 3-part, phase I\/IIa study consists of a single ascending dose (SAD) part with 32 participants, a multiple ascending dose part with 48 participants, and a drug-drug interaction part with 20 participants. Effects of food in healthy volunteers administered 45 mg HP501 in the fed state were also assessed in the SAD part.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 68 healthy volunteers and 32 hyperuricemic patients were enrolled. HP501 appeared to be safe and well tolerated in both groups. In hyperuricemic patients dosed with 45 mg HP501 over 10 days, 2\/10 and 3\/10 patients had elevated AST (&amp;lt; 2 times upper limit of normal [ULN]) and ALT (&amp;lt; 2.5 times ULN), respectively. No dose-limiting adverse events were observed. Across doses of HP501 from 5 to 60 mg, the concentrations of serum uric acid (sUA) are reduced by a maximum of about 50%. HP501 exhibited predictable pharmacokinetics across different dose levels in healthy volunteers or hyperuricemic patients. HP501 and febuxostat have obvious synergistic sUA-lowering effects with no apparent pharmacokinetics interaction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>HP501 was effective at reducing sUA in healthy volunteers and hyperuricemic patients with a tolerable safety profile, warranting further development.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac032","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T06:55:31Z","timestamp":1643784931000},"page":"1667-1678","source":"Crossref","is-referenced-by-count":4,"title":["Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I\/IIa Study"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-4219","authenticated-orcid":false,"given":"Zhenlei","family":"Wang","sequence":"first","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghai","family":"Li","sequence":"additional","affiliation":[{"name":"Hinova Pharmaceuticals Inc., Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-7350","authenticated-orcid":false,"given":"Ying","family":"Jin","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-8350","authenticated-orcid":false,"given":"Runhan","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-372X","authenticated-orcid":false,"given":"Xiangjie","family":"Di","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Hinova Pharmaceuticals Inc., Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Hinova Pharmaceuticals Inc., Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Hinova Pharmaceuticals Inc., Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-4824","authenticated-orcid":false,"given":"Li","family":"Zheng","sequence":"additional","affiliation":[{"name":"Clinical Trial Center\/NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital of Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"issue":"6","key":"2022051722321155700_CIT0001","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40620-014-0082-z","article-title":"Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling","volume":"27","author":"Liu","year":"2014","journal-title":"J Nephrol."},{"issue":"12","key":"2022051722321155700_CIT0002","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","article-title":"Gout and hyperuricaemia in the USA: prevalence and trends","volume":"58","author":"Singh","year":"2019","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"2022051722321155700_CIT0003","first-page":"3167","article-title":"Update on the epidemiology, genetics, and therapeutic options of hyperuricemia","volume":"12","author":"Li","year":"2020","journal-title":"Am J Transl Res."},{"issue":"6","key":"2022051722321155700_CIT0004","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"2022051722321155700_CIT0005","first-page":"71","article-title":"The Daniel K. Inouye College of Pharmacy Scripts: perspectives on the epidemiology of gout and hyperuricemia","volume":"78","author":"Roman","year":"2019","journal-title":"Hawaii J Med Public Health."},{"issue":"5","key":"2022051722321155700_CIT0006","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1080\/14397595.2019.1660048","article-title":"Epidemiology and prevalence of hyperuricemia among men and women in Chinese rural population: The Henan Rural Cohort Study","volume":"30","author":"Dong","year":"2020","journal-title":"Mod Rheumatol."},{"issue":"10","key":"2022051722321155700_CIT0007","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"2022051722321155700_CIT0008","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"2022051722321155700_CIT0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"2022051722321155700_CIT0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"2022051722321155700_CIT0011","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol."},{"issue":"10","key":"2022051722321155700_CIT0012","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"2","key":"2022051722321155700_CIT0013","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther."},{"issue":"Database issue","key":"2022051722321155700_CIT0014","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2022051722321155700_CIT0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update","volume":"99","author":"Saito","year":"2016","journal-title":"Clin Pharmacol Ther."},{"issue":"10264","key":"2022051722321155700_CIT0016","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/S0140-6736(20)32343-6","article-title":"FAST: new look at the febuxostat safety profile","volume":"396","author":"Bardin","year":"2020","journal-title":"Lancet."},{"issue":"13","key":"2022051722321155700_CIT0017","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2022051722321155700_CIT0018","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d","volume":"22","author":"Jansen","year":"2004","journal-title":"Clin Exp Rheumatol."},{"issue":"1217","key":"2022051722321155700_CIT0019","first-page":"U1528","article-title":"Benzbromarone therapy in management of refractory gout","volume":"118","author":"Kumar","year":"2005","journal-title":"N Z Med J."},{"issue":"9","key":"2022051722321155700_CIT0020","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00296-017-3768-4","article-title":"Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015","volume":"37","author":"Kim","year":"2017","journal-title":"Rheumatol Int."},{"issue":"9","key":"2022051722321155700_CIT0021","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"8","key":"2022051722321155700_CIT0022","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","article-title":"Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects","volume":"45","author":"Khosravan","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"2022051722321155700_CIT0023","doi-asserted-by":"crossref","first-page":"212581","DOI":"10.7573\/dic.212581","article-title":"Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout","volume":"8","author":"P\u00e9rez-Ruiz","year":"2019","journal-title":"Drugs Context."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac032\/42558541\/dgac032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/1667\/43738802\/dgac032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/1667\/43738802\/dgac032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T22:33:45Z","timestamp":1652826825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/6\/1667\/6519826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,2,2]]},"published-print":{"date-parts":[[2022,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac032","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,2,2]]}}}